Brain-Penetrating Polymeric Nanoparticles for CNS Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glioblastoma multiforme (GBM) are limited by the blood-brain barrier, which restricts drug penetration and effectiveness, leading to poor prognosis and nearly universal recurrence due to the inability to target brain cancer stem cells effectively.
Innovation Solution
Development of brain-penetrating polymeric nanoparticles optimized for intracranial convection-enhanced delivery, loaded with FDA-approved compounds that target brain cancer stem cells, allowing for enhanced penetration and prolonged release of therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional polymer nanoparticles (100-200 nm) are used for CED, then drug loading and controlled release are achieved, but penetration into brain interstitial spaces is limited due to particle size being larger than interstitial spaces (38-64 nm in normal brain, 7-100 nm in tumor regions)
Solution Approach 1:
The patent applies parameter changes by reducing the nanoparticle size from conventional 100-200 nm to 25-75 nm, specifically optimizing for 38-64 nm to match normal brain interstitial space dimensions and 7-100 nm for tumor regions. This size parameter modification enables penetration through the blood-brain barrier while maintaining drug loading capacity and controlled release properties.
Solution Approach 2:
The patent segments the nanoparticle population into different size fractions through centrifugation, separating particles into 25-75 nm (penetrating) and larger non-penetrating fractions. This segmentation allows selective delivery of therapeutically active particles to the brain tissue while removing particles that would be too large to penetrate effectively.
2Length of moving object
If drugs are delivered in aqueous suspension by CED, then penetration into brain tissue is increased, but drug half-life in the brain is short causing rapid disappearance after infusion stops
Solution Approach 1:
The patent uses polymeric nanoparticles as intermediary carriers that encapsulate therapeutic drugs. These nanoparticles serve as a reservoir that releases drugs slowly over time, extending the drug's effective half-life in the brain while maintaining penetration capability through the blood-brain barrier via convection-enhanced delivery.
Solution Approach 2:
The patent achieves continuity of useful action through sustained release from polymeric nanoparticles. The nanoparticles continuously release therapeutic agents over an extended period, maintaining effective drug concentrations in the brain tissue long after the initial infusion stops, thereby eliminating the rapid disappearance problem of aqueous suspensions.
3Quantity of substance
If direct locoregional delivery is used to bypass the BBB, then therapeutic agents can reach the brain, but penetration into tissue is limited to approximately 1 mm due to diffusion-only transport
Solution Approach 1:
The patent applies hydraulics by using convection-enhanced delivery with positive pressure gradient to create bulk fluid movement in the brain interstitium. This hydraulic approach replaces pure diffusion with active fluid flow, enabling therapeutic agents to penetrate much deeper into brain tissue beyond the 1 mm limitation of diffusion-only transport.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly increased survival in animal models by delivering therapeutic agents deeper into the brain, effectively targeting brain cancer stem cells and improving treatment outcomes for GBM.
Implementation Method 1
convection-enhanced delivery (CED), in which agents are infused into the brain under a positive pressure gradient, creating bulk fluid movement in the brain interstitium
Implementation Method 2
because drugs move from the implant into the tissue by diffusion—penetration into tissue is limited to approximately 1 mm
Data Source
AI summary
Brain-penetrating polymeric nanoparticles that can be loaded with drugs and are optimized for intracranial convection-enhanced delivery (CED) have been developed. In the preferred embodiment, these are loaded with FDA-approved compounds, identified through library screening to target brain cancer stem cells (BSCSs). The particles are formed by emulsifying a polymer-drug solution, then removing solvent and centrifuging at a first force to remove the larger particles, then collecting the smaller particles using a second higher force to sediment the smaller particles having a diameter of less than 100 nm, more preferably less than 90 nanometers average diameter, able to penetrate brain interstitial spaces.